ORIGINAL RESEARCH PAPER

Pharmaceutical Science

KEY WORDS: Potassium competitive acid blockers,proton pump inhibitors,H.pylori, Gastroesophageal Reflux Disease,peptic ulcer

POTASSIUM COMPETITIVE ACID BLOCKERS: A CLINICAL AND THERAPEUTIC REVIEW

Dr. Sunanda. Nandikol Assistant Professor, BLDEA's SSM College Of Pharmacy And Research Center, Vijayapur

Dr. Vijayshankar. M. Shirur Doctor Of Pharmacy, BLDEA's SSM College Of Pharmacy And Research Center,Vijayapur

ABSTRACT

Potassium-competitive acid blockers (P-CABs) represent a significant advancement in the management of acid-related diseases (ARDs), offering a novel mechanism distinct from traditional proton pump inhibitors (PPIs). Characterized by rapid, potent, and sustained acid suppression independent of cytochrome P450 (CYP) metabolism, P-CABs like vonoprazan and tegoprazan are redefining therapeutic strategies for gastroesophageal reflux disease (GERD), Helicobacter pylori (HP) eradication, peptic ulcer disease (PUD), and erosive esophagitis (EE). This review synthesizes current evidence on P-CAB pharmacology, clinical efficacy, safety profiles, and guideline-directed applications, highlighting their evolving role in gastroenterology.

INTRODUCTION

Gastric acid suppression remains fundamental in treating ARDs, including GERD, PUD, and HP infection. While PPIs have been the cornerstone therapy, limitations persist, including delayed onset (3–5 days for maximal effect), nocturnal acid breakthrough, significant interpatient variability due to CYP2C19 polymorphisms, and requirement for preprandial dosing to target active proton pumps (Inatomi et al., 2016; Patel et al., 2024). P-CABs, a newer class of antisecretory agents, overcome many of these constraints through reversible, potassium-competitive inhibition of H^+,K^+-ATPase, offering faster and more predictable acid control (Rawla et al., 2018).

Mechanism Of Action And Pharmacokinetics

P-CABs bind reversibly and competitively to the K^+-binding site of the luminal domain of H^+,K^+-ATPase in its E_2-P conformation, blocking acid secretion irrespective of pump activation state (Inatomi et al., 2016; Patel et al., 2024). Unlike PPIs, which are acid-labile prodrugs requiring activation in acidic environments and covalent binding to cysteine residues (e.g., Cys813), P-CABs are acid-stable, non-prodrugs. Key pharmacodynamic advantages include:

- Rapid Absorption & Onset: Peak plasma concentration (T_{max}) occurs within 1.5–2 hours. Significant acid inhibition begins within 4 hours of the first dose (Sakurai et al., 2015a; Jenkins et al., 2015).
- pH-Independent Dosing: Administration is effective regardless of meal timing due to longer plasma half-lives (6–9 hours vs. 1–2 hours for PPIs) and lack of activation dependency (Patel et al., 2024; Table 1).
- Minimal CYP2C19 Interaction: Metabolism is largely independent of CYP2C19, eliminating genetic polymorphism-related efficacy variability seen with most PPIs (Kagami et al., 2016; Patel et al., 2024).
- Potent & Sustained Suppression: Achieves higher and more prolonged intragastric pH >4 and pH >5 holding time ratios (HTR) than PPIs, particularly overnight (e.g., vonoprazan 20 mg: ~85% pH>4 HTR on Day 1 vs. ~50-60% for esomeprazole 20 mg) (Sakurai et al., 2015a; Jenkins et al., 2015; Figure 1).

Table 1: Key Pharmacological Differences Between P-CABs and PPIs

Characteristic	P-CAB (e.g.Vonoprazan)	PPI (e.g Lansoprazole)
Mechanism	Reversible	K^+-competitive ionic binding and Irreversible covalent binding to cysteines
Prodrug	No	Yes
Acid Stability	Acid-stable	Acid-labile (requires enteric coating)
Administration Timing	Independent of meals	30-60 min pre-prandial Plasma
Half-life (h)	6-9	1-2
Dosing for Max Suppression	Once daily	Often requires twice daily
Onset of Action	Rapid (within hours)	Slow (days to steady state)
CYP2C19 Dependence	Minimal/None	Significant
Examples	Vonoprazan Tegoprazan Revaprazan	Omeprazole Esomeprazole Lansoprazole etc.

(Adapted from Patel et al., 2024; Inatomi et al., 2016)

Clinical Efficacy Across Acid-Related Disorders:

- **Gastroesophageal Reflux Disease (GERD) & Erosive Esophagitis (EE)**

The American Gastroenterological Association (AGA) CPU provides nuanced Best Practice Advice (BPA) for P-CAB use in GERD/EE, emphasizing cost, availability, and comparative efficacy data (Patel et al., 2024):

Non-Erosive Reflux Disease (NERD)/ Uninvestigated Heartburn: P-CABs are not recommended as first-line therapy (BPA 3). Placebo-controlled trials show efficacy (e.g., vonoprazan 20mg: 44.4-44.8% heartburn-free days vs. 27.7% placebo; Laine et al., 2024), but superiority over double-dose PPIs is unclear, and higher costs/access barriers limit justification. P-CABs may be considered for documented acid-related reflux refractory to twice-daily PPIs (Patel et al., 2024; Table 2).

Mild EE (LA Grade A/B): P-CABs are not recommended as first-line therapy (BPA 5). Healing rates are comparable to PPIs (e.g., vonoprazan 20mg: 92-99% vs. lansoprazole 30mg: 88-100% at 8 weeks; Ashida et al., 2015, 2016; Xiao et al., 2020). Given higher cost and similar efficacy, PPIs remain preferred. P-CABs are an option for PPI failures with confirmed acid reflux (Patel et al., 2024).

Severe EE (LA Grade C/D): P-CABs are a recommended therapeutic option for healing and maintenance (BPA 6). Vonoprazan demonstrates superiority over lansoprazole in healing severe EE (e.g., 92% vs 72% at 8 weeks; Laine et al., 2023) and maintaining remission (e.g., 75-77% vs 62% at 24 weeks; Laine et al., 2023). However, marked cost differences and lack of direct comparison to double-dose PPI limit universal first-line recommendation (Patel et al., 2024; Ashida

et al., 2016).

On-Demand Therapy: Insufficient evidence exists for first-line on-demand use (BPA 4), but rapid onset makes P-CABs physiologically plausible (e.g., vonoprazan achieved 56-70% complete relief within 3h vs. 27% placebo; Fass et al., 2023) (Patel et al., 2024).

Table 2: Summary of Selected P-CAB Trials in GERD/EE

Condition	Study	P-CAB regimen	Comparator	Key Outcome (P-CAB vs Comparator)
NERD	Laine et al., 2024	Vonoprazan 10-20mg QD	Placebo	↑ % days without heartburn (44.4-44.8% vs 27.7%)
On-Demand NERD	Fass et al., 2023	Vonoprazan 10-40mg PRN	Placebo	↑ Heartburn relief within 3h sustained 24h (56-70% vs 27%)
Healing EE (Overall)	Ashida et al., 2016	Vonoprazan 20mg QD	Lansoprazole 30mg QD	Healing @8wks: 99.0% vs 95.5% (NS)
Healing EE (LA C/D)	Laine et al., 2023	Vonoprazan 20mg QD	Lansoprazole 30mg QD	Healing @8wks: 92% vs 72% (P<0.05)
Maint. Healing EE (LA C/D)	Laine et al., 2023	Vonoprazan 10/20mg QD	Lansoprazole 15mg QD	Maint. @24wks: 75-77% vs 62% (P<0.05)
Healing EE (Tegoprazan)	Lee et al., 2019	Tegoprazan 50/100mg QD	Esomeprazole 40mg QD	Healing @8wks: 95-96% vs 93% (Non-inferior)

(Patel et al., 2024; references within)

- **Helicobacter pylori Eradication**

P-CABs are strongly recommended over PPIs in most HP eradication regimens (BPA 7) (Patel et al., 2024). Their potent and rapid acid suppression elevates intragastric pH >5 more consistently, enhancing antibiotic efficacy (particularly amoxicillin) by shifting HP to a replicative state and improving drug stability (Inatomi et al., 2016; Sachs et al., 2011).

First-Line Therapy: Vonoprazan-based triple therapy (20mg BID + amoxicillin + clarithromycin) achieves significantly higher eradication rates than PPI-based triple therapy (92.6% vs 75.9%; Murakami et al., 2016). Crucially, superiority is pronounced in clarithromycin-resistant strains (82.0% vs 40.0%).

Second-Line Therapy: Vonoprazan-based regimens (e.g., with amoxicillin + metronidazole) are superior to PPI-based regimens (Odds Ratio 1.5; Shinozaki et al., 2021).

Dual Therapy & Shorter Duration: Vonoprazan (20mg BID) + high-dose amoxicillin (750mg BID) for 7 days showed promising efficacy (85% PP) comparable to 14-day PPI triple therapy (Suzuki et al., 2020; Ang et al., 2022).

Rationale For Preference: Short treatment duration mitigates long-term safety/cost concerns. Superior efficacy, especially against resistant strains, supports P-CABs as the preferred acid suppressant (Patel et al., 2024; Malfertheiner et al., 2022).

- **Peptic Ulcer Disease (PUD)**

P-CABs are not recommended as first-line therapy for PUD treatment or prophylaxis (BPA 8) (Patel et al., 2024).

Acute Healing: P-CABs (vonoprazan 20mg, tegoprazan 50-100mg) demonstrate non-inferiority to PPIs (lansoprazole 30mg) for gastric and duodenal ulcer healing (Miwa et al., 2017; Cho et al., 2020). However, higher costs and lack of clear superiority over PPIs favor continued PPI use first-line.

Secondary Prophylaxis (NSAID/Low-Dose Aspirin): Vonoprazan (10-20mg) is non-inferior to lansoprazole (15mg) in preventing ulcer recurrence during long-term NSAID/aspirin therapy in high-risk patients (Kawai et al., 2018; Mizokami et al., 2018). Despite efficacy, routine first-line use is not advised due to cost and long-term safety data limitations.

Refractory Ulcers & High-Risk Bleeding: P-CABs may be considered for PPI-refractory ulcers (if acid-related) (BPA 8). While insufficient evidence exists for first-line use in bleeding ulcers with high-risk stigmata (BPA 9), potent rapid acid suppression suggests potential utility (e.g., vonoprazan non-inferior to IV PPI pantoprazole in preventing rebleeding; Geeratragool et al., 2024) (Patel et al., 2024).

Safety Profile

P-CABs are generally well-tolerated with short-to-medium-term safety profiles comparable to PPIs (Patel et al., 2024; Ashida et al., 2016).

Common Adverse Events: Nasopharyngitis, mild constipation, or diarrhea (similar incidence to PPIs). No significant hepatotoxicity has been observed with vonoprazan/tegoprazan, unlike earlier imidazopyridine-based P-CABs (e.g., linaprazan) (Patel et al., 2024; Rawla et al., 2018).

Serum Gastrin Elevation: Significantly higher and more sustained increases in serum gastrin (and pepsinogen I/II) occur with P-CABs compared to PPIs, correlating with their greater acid suppression potency. Levels normalize within weeks of discontinuation (Ashida et al., 2015; Shinozaki et al., 2022).

Long-Term Concerns: Data beyond 5 years is limited. Long-term vonoprazan maintenance (5 years) showed adverse event rates similar to lansoprazole, with infrequent enterochromaffin-like (ECL) cell hyperplasia and rare gastric adenomas reported (no clear causal link established) (Kinoshita et al., 2023; Shinozaki et al., 2022; Arai et al., 2024 - association debated). Continuous monitoring is warranted.

Infectious Risks: Potent acid suppression may theoretically increase risks similar to PPIs (e.g., C. difficile, enteric infections). Observational data suggest vonoprazan-associated C. difficile risk is comparable to PPIs, not higher (Watanabe et al., 2021; Saruta et al., 2023). Microbiota changes reducing defenses against enteric infections have been noted (Otsuka et al., 2017).

Special Populations: Limited data exists for pregnancy/lactation, though animal studies showed no maternal/developmental toxicity with vonoprazan (Li et al., 2018).

Limitations And Future Directions

Despite advantages, limitations exist:

- **Cost and Access:** P-CABs are significantly more expensive than PPIs (especially generic) in many markets (e.g., USA) and often require prior authorization, limiting accessibility (Patel et al., 2024; BPA 1, 2).
- **Long-Term Safety Data:** Robust data beyond 5 years, particularly regarding hypergastrinemia consequences (ECL cell hyperplasia, neoplasia risk), is still emerging (Patel et al., 2024).
- **Comparative Effectiveness:** More head-to-head trials comparing P-CABs to high-dose or optimized PPI regimens (especially double-dose) are needed, particularly for cost-effectiveness analyses in GERD/EE (Patel et al., 2024; BPA 6).
- **Global Availability**: Vonoprazan is primarily approved in Asia; tegoprazan in South Korea. Revaprazan is available in South Korea and India. Access in Europe and North America is limited (Rawla et al., 2018; Patel et al., 2024).

Future research should focus on long-term outcomes, optimal dosing across diverse populations, cost-effectiveness in various healthcare systems, and exploration in novel indications like refractory GERD or Zollinger-Ellison syndrome (Patel et al., 2024).

CONCLUSION

P-CABs represent a pharmacologically advanced class of acid suppressants with distinct advantages over PPIs: rapid and potent acid inhibition from the first dose, predictable efficacy independent of CYP2C19 genotype or meal timing, and superior control of nocturnal acidity. Current evidence strongly supports their role as the preferred acid suppressant in H. pylori eradication regimens and as a valuable therapeutic option for healing and maintaining remission in severe erosive esophagitis (LA Grade C/D). However, due to significantly higher costs, access barriers, and less extensive long-term safety data compared to PPIs, they are not routinely recommended as first-line therapy for NERD, mild EE, or uncomplicated PUD. As long-term safety data accumulates and cost-effectiveness improves, the therapeutic landscape for P-CABs is poised to expand, offering a powerful tool for managing challenging acid-related disorders.

REFERENCES

1. Ang, D., Koo, S. H., Chan, Y. & Fock, K. M. (2022). Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication. Alimentary Pharmacology & Therapeutics, 56(3), 436–449. https://doi.org/10.1111/apt.17109
2. Arai, J., Miyawaki, A., Aoki, & Kawahara, T. (2024). Association between vonoprazan and the risk of gastric cancer after Helicobacter pylori eradication. Clinical Gastroenterology and Hepatology, 22(6), 1217–1225.e6. https://doi.org/10.1016/j.cgh.2023.09.023
3. Ashida, K., Sakurai, Y., Nishimura, A., ... & Iwakiri, K. (2015). Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Alimentary Pharmacology & Therapeutics, 42(6), 685–695. https://doi.org/10.1111/apt.13331
4. Ashida, K., Sakurai, Y., Hori, & Iwakiri, K. (2016). Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Alimentary Pharmacology & Therapeutics, 43(2), 240–251. https://doi.org/10.1111/apt.13461
5. Chey, W. D., Mégraud, F., Laine, & Leifker, D. (2022). Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial. Gastroenterology, 163(3), 608–619. https://doi.org/10.1053/j.gastro.2022.05.055
6. Fass, R., Vaezi, M., Sharma, & Howden, C. W. (2023). Randomised clinical trial: efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease. Alimentary Pharmacology & Therapeutics, 58(10), 1016–1027. https://doi.org/10.1111/apt.17710
7. Geeratragool, T., Kaosombatwattana, U., Boonchote, A., ... & Mahachai, V. (2024). Comparison of vonoprazan vs intravenous proton pump inhibitor for prevention of high-risk peptic ulcers rebleeding after successful endoscopic hemostasis: a multicenter randomized noninferiority trial. Gastroenterology, 167(3), 778–787.e3. https://doi.org/10.1053/j.gastro.2024.04.037
8. Inatomi, N., Matsukawa, J., Sakurai, Y., & Otake, K. (2016). Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases. Pharmacology & Therapeutics, 168, 12–22. https://doi.org/01.1016/j.pharmthera.2016.08.001
9. Jenkins, H., Sakurai, Y., Nishimura, A., & Warrington, S. (2015). Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Alimentary Pharmacology & Therapeutics, 41(7), 636–648. https://doi.org/10.1111/apt.13121
10. Kagami, T., Sahara, S., Ichikawa, & Sugimoto, M. (2016). Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Alimentary Pharmacology & Therapeutics, 43(10),1048–1059. https://doi.org/10.1111/apt.13607
11. Kawai, T., Oda, K., Funao, & Sugano, K. (2018). Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut, 67(6), 1033–1041. https://doi.org/10.1136/gutjnl-2017-314013
12. Kinoshita, Y., Haruma, K., Yao & Ashida, K. (2023). EP54 Final observation results of vision trial: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis. Gastroenterology, 164(6), S-S1202. [Abstract]
13. Laine, L., DeVault, K., Katz, P.& Howden, C. W. (2023). Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: a randomized trial. Gastroenterology, 164(1), 61–71. https://doi.org/10.1053/j.gastro.2022.09.041
14. Laine, L., Spechler, S., Yadlapati, R. & Howden, C. W. (2024). Vonoprazan is efficacious for treatment of heartburn in non-erosive reflux disease: a randomized trial [published online ahead of print]. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2024.05.004
15. Lee, K. J., Son, B. K., Kim, G. & Chun, H. J. (2019). Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs esomeprazole in patients with erosive oesophagitis. Alimentary Pharmacology & Therapeutics, 49(7), 864–872. https://doi.org/10.1111/apt.15185
16. Malfertheiner, P., Mégraud, F., Rokkas, T.& Sugano, K. (2022). Management of Helicobacter pylori infection: the Maastricht VI/Florence Consensus report. Gut, 71(9), 1724–1762. https://doi.org/10.1136/gutjnl-2022-327745
17. Mizokami, Y., Oda, K., Funao, N.& Sugano, K. (2018). Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut, 67(6), 1042–1051. https://doi.org/10.1136/gutjnl-2017-314010
18. Murakami, K., Sakurai, Y., Shiino, M., & Asaka, M. (2016). Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut, 65(9), 1439–1446. https://doi.org/10.1136/gutjnl-2015-311304
19. Patel, A., Laine, L., Moayyedi, P., & Wu, J. (2024). AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review. Gastroenterology, 167(6), 1228-1238. https://doi.org/10.1053/j.gastro.2024.06.038 (Note: Page numbers in text refer to this document's content structure)
20. Rawla, P., Sunkara, T., Ofosu, A., & Gaduputi, V. (2018). Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors? World Journal of Gastrointestinal Pharmacology and Therapeutics, 9(7), 63–68. https://doi.org/10.4292/wjgpt.v9.i7.63
21. Sakurai, Y., Mori, Y., Okamoto, H,& Shiramoto, M. (2015a). Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects — a randomised open-label cross-over study. Alimentary Pharmacology & Therapeutics, 42(6), 719–730. https://doi.org/10.1111/apt.13325
22. Saruta, Y., Watanabe, K., Tsuji, T. & Sugimoto, M. (2023). Vonoprazan poses no additional risk of developing Clostridioides difficile infection compared to proton pump inhibitors. Journal of Gastroenterology and Hepatology, 38(6), 940–947. https://doi.org/10.1111/jgh.16153
23. Shinozaki, S., Kobayashi, Y., Osawa, H., ... & Lefor, A. K. (2021). Effectiveness and safety of vonoprazan versus proton pump inhibitors for second-line Helicobacter pylori eradication therapy: systematic review and meta-analysis. Digestion, 102(3), 319–325. https://doi.org/10.1159/000504939
24. Shinozaki, S., Osawa, H., Hayashi & Yamamoto, H. (2017). Vonoprazan treatment improves gastrointestinal symptoms in patients with gastroesophageal reflux disease. Kaohsiung Journal of Medical Sciences, 33(12), 616–622. https://doi.org/10.1016/j.kjms.2017.07.004 (Illustrative safety/gastrin)
25. Suzuki, S., Gotoda, T., Kusano, C. & Iwatsuka, K. (2020). Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut, 69(6), 1019–1026. https://doi.org/10.1136/gutjnl-2019-319954
26. Watanabe, K., Shimodaira, Y., Takahashi, S., ... & Sugimoto, M. (2021). Potent acid suppression with vonoprazan vs proton pump inhibitors does not have higher association with Clostridioides difficile infection. The American Journal of Gastroenterology, 116(8), 1632–1637. https://doi.org/10.14309/ajg.0000000000001318
27. Xiao, Y., Zhang, S., Dai, N.& Chen, M. (2020). Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut, 69(2), 224–230. https://doi.org/10.1136/gutjnl-2019-318365